candesartan cilexetil / Generic mfg. - LARVOL DELTA

Microbial Metabolite 4EPS Inhibits AT1R to Reduce Blood Pressure and Aortic Aneurysm Outcome. (PubMed, Hypertension) - "in vitro, 4EPS reduced the binding of both AngII and the antagonist candesartan to AT1R and suppressed AngII-induced calcium signaling...These findings identify 4EPS as a benign, endogenous AT1R antagonist that diminishes AngII-mediated hemodynamic and vascular pathology. By suppressing cytoskeletal signaling associated with vascular remodeling, 4EPS provides significant protection against hypertension and aortic aneurysm progression in mice, revealing a previously unrecognized protective role for a gut microbial metabolite in modulating renin-angiotensin system activity."

Journal • Cardiovascular • CNS Disorders • Hypertension • APOE

Preparation and Evaluation of Candesartan Cilexetil Solid Supersaturated Self-nanoemulsion Containing Phospholipids. (PubMed, AAPS PharmSciTech) - "In the lymphatic transport experiment, compared with CC suspension, solid PC-S-SNEDDS increased the proportion of lymphatic transport from 18.69% to 62.14%. The results showed that solid PC-S-SNEDDS improved the solubility, reduced the first-pass effect, and greatly improved the bioavailability of CC, which was a promising drug delivery system to solve the problem of CC."

Journal

The First Russian Fixed Combination of Indapamide Retard and Candesartan: Results of Two Pharmacokinetic and Bioequivalence Studies. (PubMed, Kardiologiia) - "Analyte concentrations in samples were measured by a validated analytical method of high-performance liquid chromatography coupled with tandem mass spectrometry (HPLC-MS/MS). Pharmacokinetic parameters were determined for both drugs in Study 1 and for indapamide only in Study 2.Results     The 90% confidence intervals for the ratios of all Ln-transformed pharmacokinetic parameters (Cmax and AUC0-t of candesartan and indapamide in Study 1; Cmax, ss, AUC(0-τ) ss and Cτ, ss of indapamide in Study 2) were in the range of 80-125%.Conclusion    The study has proved the bioequivalence of Hyposart I (AO AKRIKHIN) to the reference concomitant drugs Atacand® (AstraZeneca AB, Sweden) and Arifon® retard (Servier Laboratories, France)."

Journal • PK/PD data

Linear IgA Bullous Dermatosis in an Elderly Patient Following Meloxicam and Candesartan Use: A Case Report. (PubMed, Cureus) - "Linear immunoglobulin A (IgA) bullous dermatosis (LABD) is a rare autoimmune blistering disorder characterized by subepidermal blisters and linear IgA deposition along the dermo-epidermal junction (DEJ). After discontinuation of the suspected culprit drug and adjustment of her antihypertensive therapy, she was treated with oral dapsone 1 mg/kg (50 mg) daily for two weeks, resulting in clinical improvement. This case underscores the importance of thorough drug history taking and early recognition of drug-induced LABD, particularly in patients on multiple medications, where identifying the true offending agent may be challenging."

Journal • Dermatology • Immunology • Orthopedics

Middle meningeal artery lidocaine infusion for refractory migraine: First case report in Portugal (EHF-EHC 2025) - "Various pharmacologic classes were tried without benefit: antihypertensives and calcium channel blockers (propranolol, candesartan, flunarizine), antiepileptics (valproic acid, topiramate, oxcarbazepine), antidepressants (amitriptyline, nortriptyline, venlafaxine, fluvoxamine, sertraline, clomipramine), other preventives (prednisolone, oxitriptan, melatonin), cycles of botulinum toxin (PREEMPT protocol), monoclonal antibodies (galcanezumab, fremanezumab, erenumab), and atogepant. At the time of the procedure, the patient was on eptinezumab 100 mg and botulinum toxin every three months but continued to have daily headaches, with severe intensity and reliance on eletriptan for acute relief... MMA lidocaine infusion has been described in few cases, and this is, to our knowledge, the first reported in Portugal. It constitutes an invasive therapeutic approach that should be considered only as a rescue option for carefully selected patients with severely refractory migraine...."

Case report • Clinical • Anorexia • CNS Disorders • Migraine • Pain

Candesartan exerts an antinociceptive effect in trigeminal pain model and reduces serotonin content in the brainstem (EHF-EHC 2025) - "Candesartan has an antinociceptive effect in the trigeminal pain model after single and repeated prophylactic administration. Its effect after repeated administration may be related to the reduction of serotonin levels in the brainstem. These results could contribute to understanding the mechanism of action of candesartan in migraine prophylaxis."

Cardiovascular • CNS Disorders • Migraine • Pain

Clinical-genotype machine prescription for migraine – A HUNT study (EHF-EHC 2025) - " In total, 475 participants tried a preventive (amitriptyline, beta-blocker, candesartan or topiramate) and 565 a triptan (371 sumatriptan) during the project period. We developed models that predicted treatment responses to amitriptyline, beta-blockers, candesartan and topiramate with modest accuracy. Incorporating genetic data did not enhance performance, although the limited sample size prevents firm conclusions. Figure 1."

Clinical • CNS Disorders • Migraine • Pain

The influence of blood pressure on susceptibility to spreading depolarization (EHF-EHC 2025) - "To examine the interplay between migraine susceptibility and chronic modulation of BP, both SHR and WKY rats were treated for three weeks with agents of distinct clinical profiles: amlodipine (antihypertension+; migraine prevention-), topiramate (migraine prevention+; antihypertension-), and candesartan (migraine prevention+; antihypertension+). Our findings highlight a link between BP and cortical excitability, which may mediate the clinical association between hypertension and increased migraine susceptibility. Modulating BP may reduce SD susceptibility, suggesting that optimizing BP control in patients with migraine may contribute to improved therapeutic outcomes, particularly in individuals with comorbid hypertension. Fig."

Cardiovascular • CNS Disorders • Hypertension • Migraine

Superiority of candesartan over topiramate in the treatment of migraine: A comparative cohort study (EHF-EHC 2025) - "Candesartan appears better tolerated and more effective than topiramate. These findings suggest a need to revise treatment guidelines to avoid exposing patients to less tolerable and less effective therapies."

Head-to-Head • CNS Disorders • Migraine • Pain

Do we still need non-specific oral prophylaxis for migraine treatment in CGRP-era? Real-life results from an Italian tertiary headache center (EHF-EHC 2025) - "Of the remaining, 354 (56%) received anti-CGRP agents and/or onabotulinumtoxinA injectios; 16 (2.5%) preferred a non-Pharmacological Treatment, and 99 (15.7%) did not need preventive prescription. Among those receiving oral prevention, the drug offered was: tricyclic antidepressants in 52 (31.9%) patients, Beta-blockers in 36 (22.1%), anticonvulsants in 19 (11.7%), Calcium Channel Blockers (flunarizine) in 26 (15.9%), SNRIs in 14 (8.6%), ACEIs/ARBs (candesartan) in 10 (3.7%) and combination of two drugs in 6 (3.7%)... A quarter of migraine patients attending our headache center received non-specific oral preventive. The most frequently prescribed treatments were antidepressants and Beta-blockers. In light of these observations, even in CGRP era, we suggest still an important role of oral conventional prophylaxis in the Headache Center setting."

Clinical • CNS Disorders • Migraine • Pain

Precision medicine in migraine: Machine learning prediction of CGRP mAb treatment outcomes (EHF-EHC 2025) - " This observational, retrospective cohort study was conducted at SkåNeuro Neurology Clinic, Lund, Sweden, including CM patients receiving preventive treatment with anti-CGRP mAbs (erenumab, fremanezumab, galcanezumab)...Candesartan led to a significant reduction in MHDs at six months (p<0.001), whereas no additional benefit was observed with botulinum toxin... Dynamic, personalized treatment enhances effectiveness of CGRP mAbs in CM. ML tools can support precision medicine by predicting likely responders and informing individualized care strategies. Fig."

Clinical • Machine learning • CNS Disorders • Migraine • Pain

Beyond CGRP receptor blockade: Exploring the mechanisms of traditional migraine prophylactic drugs propranolol and candesartan (EHF-EHC 2025) - "In CSD model, topiramate and amlodipine were also studied. These findings suggest that propranolol and candesartan may not exert their prophylactic effects via direct antagonism of CGRP receptors. Instead, inhibition of CSD may represent a mechanism underlying their prophylactic actions. Their potential presynaptic effects on endogenous CGRP release remain to be investigated."

CNS Disorders • Depression • Migraine • Pain

Dementia Care Research and Psychosocial Factors. (PubMed, Alzheimers Dement) - "Disease-modifying effects have been observed from monoclonal antibodies in symptomatic AD clinical trials. These are now being tested in Preclinical AD. ARBs may provide additional neuroprotective effects. It is also an appropriate option for those who don't have the economic or geographic means to receive monoclonal antibody infusions. With novel blood biomarkers for tau and Ab, Preclinical AD can be more easily diagnosed in the future. If this is the case, then perhaps prescribing an ARB preliminarily could slow any early pathological process occurring. In addition to a monoclonal antibody, the effects could be even more pronounced."

Journal • Review • Alzheimer's Disease • CNS Disorders • Dementia

Factors Affecting Tablet Disintegration by Immersion in Food Thickener Solution. (PubMed, Cureus) - "When Blopress® tablets containing disintegrants were immersed in a xanthan gum-based thickener solution, the disintegration time was prolonged by approximately 80-300 s, and linear regression analysis showed that this prolongation was significant. Meanwhile, the disintegration time of Norvasc® tablet (5 mg), which also contains a disintegrant, was 42 s without immersion and extended to 187 s after immersion in a thickening solution of xanthan gum for 30 min. Furthermore, the starch-based thickener solution did not affect tablet disintegration regardless of the presence or absence of disintegrants."

Journal

Pooled randomised QUARTET trials assessing effectiveness of a single pill for hypertension. (PubMed, Open Heart) - "This prospective individual participant data pooled analysis provides further evidence that the quadpill strategy is superior to initial monotherapy by virtue of improved BP-lowering, less need for uptitration and being associated with less treatment inertia."

Clinical • Journal • Cardiovascular • Hypertension

Decoding the Neuroprotective Intervention of Angiotensin Receptor Blockers: A Multimodal Approach Using In Silico Network Pharmacology, Molecular Modeling, and In Vivo Validation of Key Markers. (PubMed, ACS Chem Neurosci) - "Building on these findings, this study sought to compare the activity of azilsartan with other commonly used ARBs, including telmisartan, olmesartan, valsartan, eprosartan, irbesartan, and candesartan, using an integrative network pharmacology approach. To experimentally validate these predictions, in vivo studies were conducted in a scopolamine-induced memory-impaired model, which demonstrated significant restoration of the levels of AKT1 and PIK3CA. These findings clearly demonstrate the PI3K/AKT modulating effects of azilsartan, reinforcing its repurposing potential in dementia and related disorders, thereby expanding novel therapeutic opportunities within this drug class."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Dementia • AKT1 • PIK3CA • PIK3CB

A systematic review of commencing full dose antihypertensives in newly diagnosed hypertension. (PubMed, Blood Press) - "The review assessed commonly used antihypertensive drugs (perindopril 8 mg, ramipril 10 mg, amlodipine 10 mg, losartan 100 mg, irbesartan 300 mg, candesartan 16 mg and candesartan 32 mg) compared to low starting doses or placebo RCTs. The review indicates that initiating full dose antihypertensives for essential hypertension may be beneficial and safe. The available data are limited and further RCTs are required to assess this in specific patient groups to assess safety and efficacy."

Journal • Review • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Hypertension • Nephrology • Renal Disease

Brain-derived extracellular vesicle proteomics reveals neuroprotection induced by the ARB candesartan in Parkinson's disease patients. (PubMed, NPJ Parkinsons Dis) - "Candesartan treatment led to the differential expression of key proteins involved in PD pathogenesis: 46 in neuron-derived EVs, 48 in microglia/macrophage-derived EVs, 22 in astrocyte-derived EVs, and 92 in oligodendrocyte-derived EVs. Our findings provide the first direct molecular evidence of neuroprotective mechanisms triggered by ARBs in PD patients and support the rationale for larger clinical trials on ARB repurposing."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • Solid Tumor

Pharmacogenomics-Guided Precision Therapy for Chronic Kidney Disease with Resistant Hypertension: A Prospective Cohort Study. (PubMed, Kidney Blood Press Res) - "PGx-guided precision therapy facilitates rapid BP control, reduces polypharmacy and adverse events, and delays kidney function decline in CKD patients with RH. This study, the first PGx clinical trial targeting a multi-ethnic population in Northwest China, offers valuable insights into personalized treatment approaches for CKD with RH in East Asia."

Biomarker • Journal • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease

Candesartan, an angiotensin receptor blocker, prevents cognitive impairment in female mice with mammary cancer. (PubMed, Brain Behav Immun) - "Candesartan lowered tumour necrosis factor (Tnf) expression and improved BBB integrity in the frontal cortex, supporting its anti-inflammatory role. We provide the first evidence that candesartan may offer a low-cost strategy to prevent cancer-related cognitive impairment by modulating the RAS, neuroinflammation and BBB permeability."

Journal • Preclinical • Alzheimer's Disease • Brain Cancer • Breast Cancer • CNS Disorders • Cognitive Disorders • Oncology • Solid Tumor

Deciphering glioblastoma heterogeneity: Integrating molecular signatures and genomic landscapes to predict drug sensitivity and advance precision oncology (SNO 2025) - "Comprehensive drug screening was performed on these models, evaluating agents such as temozolomide, arsenic trioxide (ATO), TRC102, pevonedistat, TAS4464, candesartan cilexetil, selinexor, GB13, DSP-0390, and the combination of ATO with a MNK1 inhibitor. Future research will focus on analyzing CNV changes and transcriptomic differential expression within patient data and validating drug efficacy on patient-derived tumor cultures. This comprehensive strategy aims to translate preclinical discoveries into clinically relevant biomarkers, ultimately paving the way for personalized and more effective GBM treatments."

Heterogeneity • Brain Cancer • Glioblastoma • Solid Tumor

Deciphering glioblastoma heterogeneity: Integrating molecular signatures and genomic landscapes to predict drug sensitivity and advance precision oncology (WFNOS 2025) - "Comprehensive drug screening was performed on these models, evaluating agents such as temozolomide, arsenic trioxide (ATO), TRC102, pevonedistat, TAS4464, candesartan cilexetil, selinexor, GB13, DSP-0390, and the combination of ATO with a MNK1 inhibitor. Future research will focus on analyzing CNV changes and transcriptomic differential expression within patient data and validating drug efficacy on patient-derived tumor cultures. This comprehensive strategy aims to translate preclinical discoveries into clinically relevant biomarkers, ultimately paving the way for personalized and more effective GBM treatments."

Heterogeneity • Brain Cancer • Glioblastoma • Glioma • Solid Tumor

Novel APLNR antagonist candesartan induces tumor vascular normalization through ROS/cGAS/STING axis and augmented sunitinib response in breast cancer. (PubMed, J Exp Clin Cancer Res) - No abstract available

Journal • Breast Cancer • Oncology • Solid Tumor • STING

Surfactant-Enriched Cross-Linked Scaffold as an Environmental and Manufacturing Feasible Approach to Boost Dissolution of Lipophilic Drugs. (PubMed, Pharmaceutics) - " Scaffold former (Pluronic F68) and scaffold trigger agent (propylene glycol) were used to prepare cross-linked scaffold loaded with candesartan cilexetil as a model for lipophilic drugs... Surfactant-enriched cross-linked scaffold reduced environmental impact by eliminating organic solvents usage and reducing energy consumption. Moreover, it offers significant manufacturing advantages through simplified production processing."

Journal

Blocked Atrial Bigeminy as an Unusual Cause of Bradycardia: A Case Report. (PubMed, Int Med Case Rep J) - "Therapy with flecainide and amiodarone separately was not effective...The target values of blood pressure were achieved with candesartan at a dose of 32 mg...Recognition of the P wave superimposed on the ST segment or the T wave may be a clue for a correct diagnosis. Physicians should be aware of this condition to avoid unnecessary pacemaker implantation."

Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension